CUTANEOUS T CELL LYMPHOMA

This early-stage trial tests a new gene therapy for certain T-cell lymphomas that have come back or not responded to treatment. The therapy uses a patient's own white blood cells, modified to attack cancer cells that carry a protein called CCR4. Up to 60 adults will receive the m…

This study tests whether combining two drugs, pembrolizumab and mogamulizumab, can shrink or control advanced cutaneous T-cell lymphoma (a type of skin cancer) that has returned or not responded to prior therapy. About 23 adults with stage IIB to IVB disease will receive the drug…

This study tests whether a treatment called photopheresis can improve early-stage cutaneous T-cell lymphoma (a type of skin lymphoma). Normally used for advanced disease, researchers want to see if using it earlier helps clear skin lesions. About 74 adults with stage IA to IIA my…

This phase 2 trial tests a cream containing tofacitinib, a drug that calms the immune system, for people with early-stage cutaneous T-cell lymphoma (CTCL). The study will include 20 adults with stage IA, IB, or IIA disease. Researchers want to see if the cream is safe and can hel…

This phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…

This Phase 3 trial tests a gel called HyBryte, which is activated by visible light, for treating cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. About 80 adults with early-stage CTCL will apply the gel or a placebo twice a week for 18 weeks, then receive light treat…

This early-phase trial tests an investigational drug called ropeginterferon in 38 adults with cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Participants must have tried at least two prior treatments without success. The main goals are to find the safest dose and s…

This study tests the safety of combining bexarotene (a vitamin A-like drug) with ultra-low dose total skin electron beam radiotherapy for people with mycosis fungoides, a common form of cutaneous T-cell lymphoma. About 20 adults with stage IB or higher disease will receive both t…

This study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have not responded to standard therapy. The goal is to see if the drug can shrink or control the cancer. About 48 adults will take the drug by mouth, and researchers…

This early-stage trial is testing a new form of fenretinide (a vitamin A-like drug) given by IV for people with T-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The study has two parts: first, finding the safest dose in small groups of patients, …

This study tests a personalized program combining exercise and nutrition advice to help reduce fatigue in people with indolent (slow-growing) lymphomas, such as chronic lymphocytic leukemia and follicular lymphoma. Participants receive an individualized exercise plan and dietary …

This study looks at the bacteria living on the skin of people with cutaneous T cell lymphoma, a rare type of skin cancer. Researchers will compare these bacteria to those on healthy people and people with other skin conditions like psoriasis. The goal is to understand if certain …

This study collects blood, urine, and skin samples from 200 adults with cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The samples are stored and used for current and future research, such as studying proteins in the blood and tissue. Participants must have one of these…

This study looks back at medical records of 400 adults with cutaneous T-cell lymphoma (CTCL) to see which systemic therapies doctors actually use and in what order. It aims to describe real-world treatment patterns, not test a new drug. The results may help guide future treatment…